community-oncology
(5)
Joel Schaedler Is Building Scale for People Who Want to Stay Independent
A former college closer turned specialty-pharma operator, Joel Schaedler has spent his career making a stubborn idea practical: small practices can gain the advantages of scale without giving up their independence.
The Buyers' Club Keeping Cancer Clinics Independent
How a group-buying network built by former pharma executives quietly became the largest independent community-oncology network in the country - and why staying small and independent is the whole point.
Fidari
Fidari is a healthtech company building digital infrastructure for oncology navigation. Its software plugs into existing EHR systems via FHIR/HL7 to automate patient-navigation workflows, capture navigation billing revenue, and connect cancer patients to supportive and ancillary services through an integrated marketplace. Founded in 2023 and led by second-time healthcare founder Othman Ouenes, Fidari pairs AI-driven triage with human navigators to support patients from diagnosis through survivorship, while generating research-ready real-world data for life-sciences partners.
N-Power Medicine, Inc.
N-Power Medicine is a Redwood City clinical research and technology company building an always-on clinical trial infrastructure inside community oncology practices, combining a real-time registry, AI-enabled tooling, and remote site support to dramatically expand patient access to trials and shorten oncology drug development timelines.
Mark Lee
Mark Lee, MD, PhD is the CEO and Co-Founder of N-Power Medicine, a Redwood City-based company reinventing how oncology clinical trials reach patients. A medical oncologist and scientist trained at Stanford and Harvard, Lee has spent his career at the frontier of personalized medicine - from developing Oncotype DX diagnostics at Genomic Health, to helping build early cancer detection at GRAIL, to leading personalized healthcare at Genentech/Roche. In 2021, he co-founded N-Power Medicine to embed research infrastructure directly into community oncology clinics, combining AI, embedded staff, and real-time registries to dramatically expand clinical trial access. After raising a $72M Series B led by Merck's Global Health Innovation Fund, N-Power acquired Syapse in late 2024 to build the largest community-based prospective clinical research network in oncology.